{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-002295","form_type":"8-K","ticker":"KPRX","cik":"0001372514","company_name":"KIORA PHARMACEUTICALS INC","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.662744+00:00","generated_at":"2026-06-20T17:37:20.836597+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Kiora updates pipeline; KIO-301 Phase 1b results expected 1H 2023","bullets":["KIO-301 (RP) Phase 1b ABACUS trial first patient dosed Q4 2022; preliminary results expected 1H 2023.","KIO-101 (OPRA+) Phase 2 trial conditionally approved; first patient enrollment planned 1H 2023.","KIO-201 (PCED) Phase 2 trial fully enrolled Q4 2022; results and FDA registration dialogue expected 1H 2023.","Raised ~$20M gross in past 18 months; received $1.2M in R&D tax credits.","Appointed Melissa Tosca as EVP Finance; strengthened SEC reporting procedures."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-002295","json":"https://secwatch.observer/filing/0001104659-23-002295.json","markdown":"https://secwatch.observer/filing/0001104659-23-002295.md","text":"https://secwatch.observer/filing/0001104659-23-002295.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372514/000110465923002295/0001104659-23-002295-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372514/000110465923002295/tm232667d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:37:20.836597+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}